STOCK TITAN
  1. Home
  2. News
  3. XNCR

Xencor to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:

  • Guggenheim Healthcare Talks | 2021 Oncology Days
    Conference Dates: February 11-12, 2021
    Presentation Date: Thursday, February 11, 2021
    Presentation Time: 1:00 p.m. EST / 10:00 a.m. PST
  • 10th Annual SVB Leerink Global Healthcare Conference
    Conference Dates: February 22-26, 2021
    Presentation Date: Wednesday, February 24, 2021
    Presentation Time: 3:00 p.m. EST / 12:00 p.m. PST

Live webcasts of the presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Replays will be posted on the Xencor website approximately one hour after the live event and will be available for at least 30 days.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Stock XNCR logo
Xencor, Inc.

NASDAQ:XNCR

XNCR Rankings

#2153 Ranked by Market Cap
#4337 Ranked by Stock Gains
N/A Ranked by Dividends

XNCR Latest News

Apr 9, 2024
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Feb 28, 2024
Xencor to Present at Upcoming Investor Conferences
Feb 27, 2024
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 20, 2024
Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
Jan 3, 2024
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference

XNCR Stock Data

1.49B
55.23M
0.98%
105.64%
9.71%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PASADENA

About XNCR

antibodies by design antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. at xencor, we apply proprietary protein engineering technologies to develop better biotherapeutics – antibodies that target new biological mechanisms and are more potent, safer and longer lasting – to improve patient outcomes and quality of life. our xmab antibody engineering technology dramatically augments natural antibody immune functions while maintaining over 99.5% identity to natural antibodies. this combination of new, highly potent activities while maintaining the beneficial drug features and simplicity of natural antibodies allows us to create differentiated drug candidates with potential for breakthrough performance. the xmab® platform has resulted in a robust pipeline of antibody product candidates, including eight in human clinical trials being developed by xencor and by pharmaceutical partners. xencor is also discovering biologics product